Trial Profile
An open-label phase IIb study to evaluate the safety, tolerability and efficacy of Fotolon as a photosensitising agent for the local treatment of airway-obstructing non small cell lung cancer (NSCLC) with photodynamic therapy (PDT)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Feb 2018
Price :
$35
*
At a glance
- Drugs Chlorine-E6 (Primary)
- Indications Airway obstruction; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors APOCARE Pharma
- 15 Feb 2018 Status changed from recruiting to completed.
- 24 Oct 2014 New trial record